STEPHANIE SLOUGH: Open Payments
NPI 1124539895 · COMMERCE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$794 in 45 payments from 19 companies in 2025. Trend: 2023 $817 · 2024 $689 · 2025 $794
Food & beverage: $794
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 9 | $135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $101 |
| Teva Pharmaceuticals USA, Inc. | 5 | $88 |
| PFIZER INC. | 3 | $75 |
| Novo Nordisk Inc | 4 | $70 |
| AstraZeneca Pharmaceuticals LP | 4 | $69 |
| ABIOMED | 1 | $39 |
| ABBVIE INC. | 2 | $33 |
| Lundbeck LLC | 1 | $22 |
| Viatris Specialty LLC | 1 | $20 |
Products named: TRELEGY ELLIPTA, CAPLYTA, AUSTEDO XR, ELIQUIS, BREZTRI, REXULTI, Ozempic, YUPELRI.
Industry payments across TX — which companies pay providers there.
